Reportable Segment Information (Tables)

12 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Segment Revenue, Operating (Loss) Income and Depreciation and Amortization

Segment revenue, operating (loss) income, and depreciation and amortization were as follows:

	Fiscal Year
(In thousands)	2020			2019			2018
Revenue:
Medical Device	$	71,401		$	78,353		$	60,513
In Vitro Diagnostics		23,463			21,724			20,823
Total revenue	$	94,864		$	100,077		$	81,336
Operating (loss) income:
Medical Device	$	(3,246	)	$	4,794		$	(8,478	)
In Vitro Diagnostics		11,771			10,620			8,619
Total segment operating (loss) income		8,525			15,414			141
Corporate		(9,776	)		(8,945	)		(8,940	)
Total operating (loss) income	$	(1,251	)	$	6,469		$	(8,799	)
Depreciation and amortization:
Medical Device	$	6,223		$	5,811		$	5,376
In Vitro Diagnostics		483			464			394
Corporate		557			1,037			661
Total depreciation and amortization	$	7,263		$	7,312		$	6,431

Revenue from Customers

Revenue from customers that equaled or exceeded 10% of total revenue was as follows:

	Fiscal Year
	2020			2019			2018
Abbott		19	%		19	%		11	%
Medtronic		14	%		14	%		16	%

Geographic Revenue and Long-lived Assets

Revenue by geographic region was as follows:

	Fiscal Year
	2020			2019			2018
Domestic		78	%		81	%		79	%
Foreign		22	%		19	%		21	%

Long-lived assets by country, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, were as follows:

	September 30,
(In thousands)	2020		2019
U.S.	$	25,273	$	24,450
Ireland		18,113		19,524